This company has been marked as potentially delisted and may not be actively trading. Zevra Therapeutics (KMPH) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock KMPH Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International ...September 4, 2025 | markets.businessinsider.comZevra Therapeutics’ Earnings Call: Optimism Amid ChallengesAugust 15, 2025 | msn.comZevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.'August 14, 2025 | msn.comZevra Therapeutics Inc options imply 12.4% move in share price post-earningsAugust 12, 2025 | msn.comZevra Therapeutics reports Q2 EPS $1.21, consensus $1.38August 12, 2025 | msn.comA Look at Zevra Therapeutics's Upcoming Earnings ReportAugust 11, 2025 | benzinga.comHere's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)July 15, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy RecommendationJuly 2, 2025 | msn.comZevra Therapeutics signals accelerated MIPLYFFA adoption and $148.3M capital infusion while expanding global reachMay 14, 2025 | msn.comZevra Therapeutics closes sale of Rare Disease PRV for $150MApril 8, 2025 | markets.businessinsider.comZevra Therapeutics price target raised to $25 from $23 at CanaccordMarch 13, 2025 | markets.businessinsider.comZevra Therapeutics price target raised to $22 from $20 at GuggenheimMarch 13, 2025 | markets.businessinsider.comZevra Therapeutics reports Q4 EPS (67c), consensus (40c)March 12, 2025 | markets.businessinsider.comZevra Therapeutics to Sell Priority-Review Voucher for $150 MillionFebruary 27, 2025 | marketwatch.comZevra Therapeutics to sell Rare Pediatric Disease PRV for $150MFebruary 27, 2025 | markets.businessinsider.comZevra Therapeutics (ZVRA) Gets a Buy from Roth MKMFebruary 10, 2025 | markets.businessinsider.comZevra Therapeutics price target raised to $21 from $20 at GuggenheimFebruary 4, 2025 | markets.businessinsider.comZevra Therapeutics to be added to Nasdaq Biotechnology IndexDecember 18, 2024 | markets.businessinsider.comZevra Therapeutics Gains Buy Rating Amid Successful MIPLYFFA Launch and Strong Market ResponseNovember 22, 2024 | markets.businessinsider.comZevra Therapeutics announces U.S. commercial availability of MIPLYFFANovember 21, 2024 | markets.businessinsider.comZevra Therapeutics Gains Momentum with Miplyffa Approval and Market Expansion Potential in Rare Disease TreatmentNovember 21, 2024 | markets.businessinsider.comZevra Therapeutics: Buy Rating Backed by Strong Pipeline and Experienced Leadership in Rare Disease MarketNovember 19, 2024 | markets.businessinsider.comZevra Therapeutics: Promising Launch Prospects and Strategic Initiatives Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comZevra Therapeutics price target lowered to $23 from $25 at CanaccordNovember 14, 2024 | markets.businessinsider.comZevra Therapeutics (ZVRA) Receives a Buy from Roth MKMNovember 14, 2024 | markets.businessinsider.comZevra Therapeutics’ Transformative Third Quarter 2024November 13, 2024 | markets.businessinsider.comZevra Therapeutics (NASDAQ:ZVRA) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comZevra Therapeutics IncSeptember 25, 2024 | reuters.comJMP Securities Initiates Coverage of Zevra Therapeutics (ZVRA) with Market Outperform RecommendationSeptember 24, 2024 | msn.comBuy Rating Affirmed for Zevra Therapeutics Amidst Strong Market Potential and Innovative PipelineSeptember 24, 2024 | markets.businessinsider.comFDA approves Zevra Therapeutics’ Miplyffa for Niemann-Pick diseaseSeptember 23, 2024 | msn.comZevra Therapeutics prices rare genetic disorder drug at up to $106,000 per monthSeptember 23, 2024 | msn.comZevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type CSeptember 21, 2024 | markets.businessinsider.comZevra Therapeutics: A Strong Buy on Miplyffa’s Approval and Market PotentialSeptember 21, 2024 | markets.businessinsider.comZevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative DiseaseSeptember 21, 2024 | benzinga.comFDA Approves Zevra Therapeutics' MIPLYFFA For Treatment Of Niemann-Pick Disease Type CSeptember 21, 2024 | markets.businessinsider.comUS FDA approves Zevra's treatment for rare genetic diseaseSeptember 20, 2024 | msn.comUS FDA approves Zevra's genetic disorder treatmentSeptember 20, 2024 | reuters.comZevra Therapeutics Mixed Q2 Results: DetailsAugust 13, 2024 | msn.comWhat Wall Street expects from Zevra Therapeutics's earningsAugust 13, 2024 | markets.businessinsider.comZevra Therapeutics Q2 2024 Earnings PreviewAugust 12, 2024 | msn.comCorcept Therapeutics (NASDAQ:CORT) Stock Quotes, Forecast and News SummaryAugust 10, 2024 | benzinga.comZevra Therapeutics launches public stock offeringAugust 10, 2024 | investing.comZevra Therapeutics Shares Fall Premarket on Stock OfferingAugust 9, 2024 | marketwatch.comZevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth ConferenceAugust 7, 2024 | markets.businessinsider.comZevra: FDA Advisory Committee Votes Favorably on Arimoclomol for NPC PatientsAugust 3, 2024 | marketwatch.comBuy Rating Affirmed for Zevra Therapeutics Amidst Positive Developments for NPC Drug ArimoclomolAugust 2, 2024 | markets.businessinsider.comInsiders Buying Zevra Therapeutics And 1 Other StockJuly 19, 2024 | msn.comStrong Buy Rating for Zevra Therapeutics Based on Solid Financials and Promising Drug PipelineMay 9, 2024 | markets.businessinsider.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | msn.com Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KMPH Media Mentions By Week KMPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KMPH News Sentiment▼0.000.92▲Average Medical News Sentiment KMPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KMPH Articles This Week▼00▲KMPH Articles Average Week Get the Latest News and Ratings for KMPH and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Zevra Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MBX News AVTE News BIOA News ELYM News CYBN News VIRI News OSTX News ATNM News AADI News EGRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KMPH) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
